Comparing of Idera Pharmaceuticals Inc. (IDRA) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Idera Pharmaceuticals Inc. N/A 90.85 62.66M -2.48 0.00
Tonix Pharmaceuticals Holding Corp. N/A 0.00 23.99M -28.85 0.00

Demonstrates Idera Pharmaceuticals Inc. and Tonix Pharmaceuticals Holding Corp. earnings per share (EPS), gross revenue and valuation.


Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Idera Pharmaceuticals Inc. 0.00% -68.4% -60.4%
Tonix Pharmaceuticals Holding Corp. 0.00% -131.9% -116.8%

Volatility and Risk

Idera Pharmaceuticals Inc. has a 2.22 beta, while its volatility is 122.00%, thus making it more volatile than Standard & Poor’s 500. Tonix Pharmaceuticals Holding Corp.’s 20.00% more volatile than Standard & Poor’s 500 which is a result of the 1.2 beta.


Idera Pharmaceuticals Inc.’s Current Ratio is 8.2 while its Quick Ratio is 8.2. On the competitive side is, Tonix Pharmaceuticals Holding Corp. which has a 6.8 Current Ratio and a 6.8 Quick Ratio. Idera Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Tonix Pharmaceuticals Holding Corp.

Analyst Recommendations

Idera Pharmaceuticals Inc. and Tonix Pharmaceuticals Holding Corp. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Idera Pharmaceuticals Inc. 0 0 1 3.00
Tonix Pharmaceuticals Holding Corp. 0 0 0 0.00

Idera Pharmaceuticals Inc.’s consensus price target is $14, while its potential upside is 469.11%.

Insider & Institutional Ownership

Roughly 44.4% of Idera Pharmaceuticals Inc. shares are held by institutional investors while 12.2% of Tonix Pharmaceuticals Holding Corp. are owned by institutional investors. Insiders held 0.4% of Idera Pharmaceuticals Inc. shares. Insiders Comparatively, held 0.3% of Tonix Pharmaceuticals Holding Corp. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Idera Pharmaceuticals Inc. -4.51% -28.7% -29.39% -57.51% -57.51% -61.14%
Tonix Pharmaceuticals Holding Corp. -47.59% -58.09% -66.83% -93.64% -92.8% -92.12%

For the past year Idera Pharmaceuticals Inc.’s stock price has smaller decline than Tonix Pharmaceuticals Holding Corp.


Idera Pharmaceuticals Inc. beats Tonix Pharmaceuticals Holding Corp. on 7 of the 8 factors.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.